RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Anita Afzali  ¹     Michael Chiorean  ²     Garrett Lawlor  ³     Mark T. Osterman     Arteid Memaj     Remo Panaccione  ⁴     Subrata Ghosh  ^5    
1 The Ohio State University Wexner Medical Center, Columbus, United States
² Swedish Medical Group, Seattle, United States
³ Bristol Myers Squibb, Princeton, United States
⁴ Inflammatory Bowel Disease Clinic, University of Calgary, Calgary, Canada
⁵ College of Medicine and Health, University College Cork, Cork, Ireland

Session
Clinical trials in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)